このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

オラパリブとベバシズマブの併用による利益につながるHRDの状況(STROBE試験) (STROBE)

2026年11月16日 更新者:Vall d'Hebron Institute of Oncology

進行性FIGOステージIII-IVの高悪性度漿液性または子宮内膜性卵巣、卵管、または腹膜の患者を対象とした、オラパリブとベバシズマブの併用による利益につながるHRDの状態をより詳細に特徴付けるための非無作為化非盲検前向き第II相試験標準的な一次治療後のがん

Background:

The study aims to address the challenge of accurately identifying patients with ovarian cancer who would benefit from poly-ADP ribose inhibitors (PARPi) as first-line maintenance therapy. While BRCA1/2-mutated epithelial ovarian cancer (EOC) patients have shown significant benefits from PARPi treatment, the efficacy in homologous recombination deficient (HRD) patients remains inconclusive. Current assays used to estimate HR status do not effectively differentiate between patients who benefit most from PARPi and those who do not, making it inefficient to treat all patients. There is a need for a more accurate HR status testing method to optimize PARPi benefit. This study aims to assess the performance of the VHIO-CARD-300 test in determining HR status compared to SOPHiA DDM™ Dx HRD Solution.

Summary:

The study is a prospective, non-randomized trial designed to evaluate the concordance of the VHIO-CARD-300 test in establishing HR status compared to SOPHiA DDM™ Dx HRD Solution. Additionally, it aims to assess the association between HRD status determined by the VHIO-CARD-300 test and treatment efficacy. Patients with advanced FIGO stage III-IV high grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer will be invited to participate. Those eligible will undergo testing with both VHIO-CARD-300 and SOPHiA DDM™ Dx HRD Solution. Patients classified as HRD positive will receive olaparib in combination with bevacizumab, while others will receive bevacizumab alone. Treatment will be administered according to approved doses, with follow-up evaluations conducted until RECIST progression.

調査の概要

状態

募集

条件

詳細な説明

This non-randomized, open-label phase II trial seeks to enhance our understanding of HRD status in patients with advanced ovarian, fallopian tube, or peritoneal cancer. Following standard first-line treatment, participants will be assessed for HRD status using the VHIO-CARD-300 test and SOPHiA DDM™ Dx HRD Solution. Those identified as HRD-positive will receive olaparib in combination with bevacizumab, while others will receive bevacizumab alone as per standard care. The study aims to determine the concordance between the two HRD tests, evaluate the efficacy of the olaparib-bevacizumab combination, and assess safety and tolerability. Efficacy outcomes will be evaluated using RECIST criteria, with a minimum follow-up of 30 months post-enrollment. Secondary objectives include examining treatment accuracy, association with efficacy outcomes, and analyzing discrepant cases. Overall, this trial aims to provide valuable insights into personalized treatment approaches for patients with advanced ovarian cancer.

研究の種類

介入

入学 (推定)

100

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Ana Oaknin
  • 電話番号:2658 +34 934893000
  • メール:aoaknin@vhio.net

研究場所

      • Barcelona、スペイン
        • 募集
        • Vall d'Hebron Institute of Oncology
        • コンタクト:
          • Ana Oaknin

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

女性

説明

Inclusion Criteria:

  1. Patient with newly diagnosed high- grade serous or endometrioid Ovarian cancer, primary peritoneal cancer and/or fallopian-tube cancer. I-3-3 At an advanced stage: FIGO stage IIIB, IIIC, or IV of the 1988 FIGO classification (see appendix 1).

  2. Patient who has completed prior to enrollment first line platinum-taxane chemotherapy:

    1. Platinum-taxane based regimen must have consisted of
    2. minimum of 6 treatment cycles and a maximum of 8. However, if platinum-based therapy must be discontinued early as a result of non-hematological toxicityspecificallyrelated to the platinum regimen, (i.e. neurotoxicity, hypersensitivity etc.), patient must have received a minimum of 4 cycles of the platinum regimen.
    3. Patient must have received prior to enrollment a minimum of 3 cycles of bevacizumab in combination with the 3 last cycles of platinum-based chemotherapy. Only in case of interval debulking surgery, it is allowed to realize only 2 cycles of bevacizumab in combination with the last 3 cycles of platinum-based chemotherapy.
  3. Patient must be prior to enrollment without evidence of disease (NED) or in complete response (CR) or partial response (PR) from the first line treatment. There should be no clinical evidence of disease progression (physical exam, imagery, CA 125) throughout he first line treatment and prior to study enrollment.

  4. Patient must be randomized at least 4 weeks and no more than 8 weeks after her last dose of chemotherapy (last dose is the day of the last infusion) and all major toxicities from theprevious chemotherapy must have resolved to CTCAE grade 1 or better (except alopecia and peripheral neuropathy).

  5. Patient must have normal organ and bone marrow function:

  6. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (see appendix 3)

  7. Formalin fixed, paraffin embedded (FFPE) tumor sample from the primary cancer must be available for central BRCA testing and test result must be available for stratification.

Exclusion Criteria:

  1. Non-epithelial origin of the ovary, the fallopian tube or the peritoneum (i.e. germ cell tumors).

  2. Ovarian tumors of low malignant potential (e.g. borderline tumors) or mucinous carcinoma.

  3. Other malignancy within the last 5 years except:

  4. Patient with myelodysplastic syndrome/acute myeloid leukemia history.

  5. Major surgery within 4 weeks of starting study treatment and patient must have recovered from any effects of any major surgery.

  6. Any previous treatment with PARP inhibitor, including olaparib.

  7. Concomitant use of known potent CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, telithromycin, clarithromycin and nelfinavir.

  8. Prior history of hypertensive crisis (CTC-AE grade 4) or hypertensive encephalopathy.

  9. Clinically significant (e.g. active) cardiovascular disease, including:

    1. Myocardial infarction or unstable angina within ≤ 6 months of enrollment,
    2. New York Heart Association (NYHA) ≥ grade 2 congestive heart failure (CHF) (see appendix 5).
    3. Poorly controlled cardiac arrhythmia despite medication (patient with rate controlled atrial fibrillation are eligible), or any clinically significant abnormal finding on resting ECG,
    4. Peripheral vascular disease grade ≥ 3 (e.g. symptomatic and interfering with activities of daily living [ADL] requiring repair or revision)
  10. Previous Cerebro-Vascular Accident (CVA), Transient Ischemic Attack (TIA) or Sub-Arachnoids Hemorrhage (SAH) within 6 months prior to enrollment.

  11. History or evidence of hemorrhagic disorders within 6 months prior to enrollment.

  12. History or clinical suspicion of brain metastases or spinal cord compression.

  13. Significant traumatic injury during 4 weeks prior to enrollment.

  14. Non-healing wound, active ulcer or bone fracture.

  15. History of VEGF therapy related abdominal fistula or gastrointestinal perforation or active gastrointestinal bleeding within 6 months prior to the first study treatment.

  16. Current, clinically relevant bowel obstruction, including sub-occlusive disease, related to underlying disease.

  17. Patient with evidence of abdominal free air not explained by paracentesis or recent surgical procedure.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:HRD positive arm

Patient with harboring HRD tumor, that will receive olaparib in combination with bevacizumab

Bevacizumab dosing is at 15 mg/kg every 3 weeks as an intravenous infusion.

Olaparib dosing is oral at 300 mg twice daily

他の:HRD negative arm

Control group receiving bevacizumab alone as standard of care.Patient with non harboring HRD tumor, that will receive bevacizumab

Bevacizumab dosing is at 15 mg/kg every 3 weeks as an intravenous infusion.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Concordance in HRD status identification between VHIO-CARD-300 test and SOPHiA DDM™ Dx HRD Solution
時間枠:Through study completion, an average of 1.5 years

The primary outcome measure description would outline the method used to evaluate the agreement in HRD status identification between the VHIO-CARD-300 test and SOPHiA DDM™ Dx HRD Solution. This would include details on how HRD status is determined and compared between the two tests, along with any statistical analyses employed to measure the level of agreement.

Through study completion, an average of 1.5 years

二次結果の測定

結果測定
メジャーの説明
時間枠
Performance Assessment of VHIO-CARD-300 Test for HR Status Identification
時間枠:Through study completion, an average of 1.5 years

This secondary outcome measure focuses on evaluating the performance of the VHIO-CARD-300 test as a diagnostic tool for identifying HR status. The assessment will include determining the sensitivity, specificity, and predictive positive and negative values of the VHIO-CARD-300 test, with the SOPHiA DDM™ Dx HRD Solution serving as the reference standard.

Through study completion, an average of 1.5 years
Association Between VHIO-CARD-300 Test Groups and Efficacy Outcomes(i.e., HRD positive and HRD negative) and efficacy outcomes.
時間枠:Through study completion, an average of 1.5 years

To assess the relationship between the HRD positive and HRD negative groups identified by the VHIO-CARD-300 test and treatment efficacy outcomes.

Through study completion, an average of 1.5 years
Analysis of Progression-Free Survival (PFS) and Overall Survival (OS) in Discrepant HRD Cases
時間枠:Through study completion, an average of 1.5 years

This outcome measure aims to assess the efficacy outcomes in cases where there is a discrepancy between the results obtained from the VHIO-CARD-300 test and the SOPHiA DDM™ Dx HRD Solution. Specifically, it focuses on cases where a patient is classified as HRD positive by one test but HRD negative by the other, and vice versa. The primary efficacy endpoints, progression-free survival (PFS) and overall survival (OS), will be analyzed in these discrepant cases to evaluate the impact of the discordant results on clinical outcomes

Through study completion, an average of 1.5 years
Safety and Tolerability of Olaparib Plus Bevacizumab
時間枠:Through study completion, an average of 1.5 years

Assessment of adverse events (AEs) graded by the National Cancer Institute (NCI) CTCAE v5.0, serious adverse events (SAEs), abnormal vital signs, abnormal ECG results, and evaluation of laboratory parameters

Through study completion, an average of 1.5 years
To evaluate the failure rate for the VHIOCARD-300 test and SOPHiA DD Dx HRD Solution.
時間枠:Through study completion, an average of 1.5 years

Percentage of inconclusive results will be estimated for each test

Through study completion, an average of 1.5 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Ana Oaknin、Vall d'Hebron Institute of Oncology

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年2月6日

一次修了 (実際)

2024年3月1日

研究の完了 (推定)

2027年9月1日

試験登録日

最初に提出

2024年4月10日

QC基準を満たした最初の提出物

2024年4月16日

最初の投稿 (実際)

2024年4月22日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月17日

QC基準を満たした最後の更新が送信されました

2026年11月16日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する